Simcere Expands Zemprocitinib Deal With Lynk
Simcere gains exclusive dermatology rights to zemprocitinib across Greater China under an expanded collaboration with Lynk Pharmaceuticals.
Updated on Nov. 2, 2026 in Arthritis
Lynk Pharmaceuticals has expanded its commercialization collaboration with Simcere Pharmaceutical Group for zemprocitinib, an oral JAK1 inhibitor. Simcere will obtain exclusive commercialization rights in Chinese Mainland, Macau, Hong Kong and Taiwan for dermatology indications.
Why it matters
The expansion extends an existing 2022 rheumatology and immunology partnership into dermatology, covering moderate-to-severe atopic dermatitis in adults. The companies say the arrangement should further support market development and patient access for the drug.
Zemprocitinib has completed a pivotal Phase III study in adults with moderate-to-severe atopic dermatitis, and its New Drug Application was accepted for review by China's Center for Drug Evaluation in April 2026. The source does not disclose efficacy comparisons against placebo or existing therapies, nor a projected approval date.
The players
Lynk Pharmaceuticals
A Hangzhou-based drug developer whose zemprocitinib is an oral, highly selective second-generation JAK1 inhibitor in clinical development.
Simcere Pharmaceutical Group
A Shanghai-based pharmaceutical company that commercializes drugs across China and holds the expanded rights to zemprocitinib.
The details
Simcere will gain exclusive commercialization rights for dermatology indications in Chinese Mainland, Macau, Hong Kong and Taiwan. The rights build on the March 2022 agreement covering rheumatoid arthritis and ankylosing spondylitis, while the rheumatoid arthritis Phase III study has been completed and the ankylosing spondylitis program is underway.
Timeline
March 2022: Lynk and Simcere sign initial collaboration covering RA and AS.
April 2026: China's Center for Drug Evaluation accepts zemprocitinib NDA for review.
November 2, 2026: Expanded dermatology collaboration announced.
Health Landscape
Zemprocitinib is an oral JAK1 inhibitor, a class of drugs that has increasingly been developed for inflammatory conditions beyond rheumatology, including atopic dermatitis. This expansion places the molecule in the same therapeutic direction as the broader JAK inhibitor movement away from injectable biologics for chronic skin and joint disease.
For patients with moderate-to-severe atopic dermatitis in the covered regions, an approved oral option would be a different route than topical or injectable therapies. Availability depends on regulatory approval, which the source does not date.
The takeaway
Oral JAK inhibitors are being tested across several inflammatory conditions, so readers with atopic dermatitis or joint disease should watch for regulatory decisions rather than assume near-term access. Discuss treatment options with a clinician when new drugs become available.
Further reading
Explore more on Arthritis, where zemprocitinib's rheumatology program sits alongside its newer dermatology work.
